- Home
- EDIT vs OVID Comparison
EDIT vs OVID Comparison
Compare EDIT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDIT | OVID |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.4M | 522.6M |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EDIT | OVID |
|---|---|---|
| Price | $2.82 | $2.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $5.30 | $4.60 |
| AVG Volume (30 Days) | ★ 2.7M | 1.8M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,937,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 132.64 | ★ 1181.27 |
| 52 Week Low | $1.66 | $0.27 |
| 52 Week High | $4.54 | $3.11 |
Technical Indicators
Market Signals| Indicator | EDIT | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 40.55 |
| Support Level | $2.77 | $2.33 |
| Resistance Level | $3.27 | $2.38 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 29.08 | 7.02 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.